IN8BIO, INC.
INABDrugs in Pipeline
2
Phase 3 Programs
0
Upcoming Catalysts
0
Next Catalyst
None scheduled
Market Overview
Stock performance and key metrics
0 upcoming, 0 past
No catalysts found.
Autologous genetically modified gamma-delta T cells
Glioblastoma
INB-100
Acute Myeloid Leukemia (post haploidentical stem cell transplant)
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Autologous genetically modified gamma-delta T cells | Phase 2 | Glioblastoma | - | - |
INB-100 | Phase 1 | Acute Myeloid Leukemia (post haploidentical stem cell transplant) | - | - |
Frequently asked questions
What is in IN8BIO, INC.'s drug pipeline?→
CatalystAlert tracks 2 drug candidates in IN8BIO, INC.'s (INAB) pipeline across Phase 2, Phase 1. Its lead program is Autologous genetically modified gamma-delta T cells (Phase 2). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is IN8BIO, INC.'s next FDA catalyst?→
CatalystAlert tracks every upcoming catalyst for IN8BIO, INC. (INAB) — PDUFA decision dates, Phase 1/2/3 trial readouts, FDA advisory committee meetings and NDA/BLA filings — each confidence-rated as confirmed, estimated or AI-detected.
How do I track INAB biotech catalysts?→
Add INAB to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow IN8BIO, INC.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.